BCL2 and triple-negative breast carcinoma: For example, in other subject areas, Alhoshani et al. found that venetoclax (BCL2 inhibitor) could suppress the cell growth and proliferation of triple-negative breast carcinoma by inducing autophagy-associated cell apoptosis and cycle arrest, as well as death [70].